Evidence map›Paper›PMID 34888524›Full record

ArticleNAR cancer2021

Correction to 'Tumor-selective, antigen-independent delivery of a pH sensitive peptide-topoisomerase inhibitor conjugate suppresses tumor growth without systemic toxicity'.

Sophia Gayle, Robert Aiello, Nalin Leelatian, Jason M Beckta, Jane Bechtold, Patricia Bourassa, Johanna Csengery, Robert J Maguire, Dan Marshall, Ranjini K Sundaram and 14 more

Open access · goldAbstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in NAR cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 54% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

24 authors at 2 institutions in 1 country.

Sophia GayleCybrexa Therapeutics, New Haven, CT 06511, USA.
Robert AielloCybrexa Therapeutics, New Haven, CT 06511, USA.
Nalin LeelatianDepartment of Pathology, Yale University School of Medicine, New Haven, CT 06520, USA.
Jason M BecktaDepartment of Therapeutic Radiology, Yale University School of Medicine, New Haven, CT 06520, USA.
Jane BechtoldCybrexa Therapeutics, New Haven, CT 06511, USA.
Patricia BourassaCybrexa Therapeutics, New Haven, CT 06511, USA.
Johanna CsengeryCybrexa Therapeutics, New Haven, CT 06511, USA.
Robert J MaguireCybrexa Therapeutics, New Haven, CT 06511, USA.
Dan MarshallCybrexa Therapeutics, New Haven, CT 06511, USA.
Ranjini K SundaramDepartment of Therapeutic Radiology, Yale University School of Medicine, New Haven, CT 06520, USA.
Jinny Van DoornDepartment of Therapeutic Radiology, Yale University School of Medicine, New Haven, CT 06520, USA.
Kelli JonesCybrexa Therapeutics, New Haven, CT 06511, USA.
Hunter MooreCybrexa Therapeutics, New Haven, CT 06511, USA.
Lori Lopresti-MorrowCybrexa Therapeutics, New Haven, CT 06511, USA.
Timothy ParadisCybrexa Therapeutics, New Haven, CT 06511, USA.
Laurie TylaskaCybrexa Therapeutics, New Haven, CT 06511, USA.
Qing ZhangCybrexa Therapeutics, New Haven, CT 06511, USA.
Hannah ViscaPhysics Department, University of Rhode Island, Kingston, RI 02881, USA.
Yana K ReshetnyakPhysics Department, University of Rhode Island, Kingston, RI 02881, USA.
Oleg A AndreevPhysics Department, University of Rhode Island, Kingston, RI 02881, USA.
Donald M EngelmanDepartment of Molecular Biophysics and Biochemistry, Yale University, New Haven, CT 06511, USA.
Peter M GlazerDepartment of Therapeutic Radiology, Yale University School of Medicine, New Haven, CT 06520, USA.
Ranjit S BindraDepartment of Pathology, Yale University School of Medicine, New Haven, CT 06520, USA.ORCID https://orcid.org/0000-0002-3255-0467
Vishwas M ParalkarCybrexa Therapeutics, New Haven, CT 06511, USA.
Yale University · USUniversity of Rhode Island · US

Funding

TM INTERACTIONS IN MEMBRANE PROTEIN FOLDING AND FUNCTIONR01GM073857 · NIGMS · YALE UNIVERSITY · PI ANDREEV, OLEG A, ENGELMAN, DONALD M. · 2006 to 2023
$8.4M
Exploiting Mutant IDH1/2-induced Homologous Recombination Defects in CancerR01CA215453 · NCI · YALE UNIVERSITY · PI BINDRA, RANJIT · 2017 to 2021
$1.9M
NCI NIH HHS R01 CA215453NIGMS NIH HHS R01 GM073857
6 · The paper itself

Abstract

[This corrects the article DOI: 10.1093/narcan/zcab021.].

Identifiers

PMID34888524
PMCPMC8651162
OpenAlexW4200544137

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.